Pfizer’s IV Revatio, when added to inhaled nitric oxide, failed to meet the primary efficacy endpoint in treating newborns with persistent pulmonary hypertension in a Phase III study.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-07-01 10:41:432019-07-01 13:14:53Pfizer Reports Failure in PPHN, Progress in DMD
